MX2011007307A - Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo. - Google Patents

Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo.

Info

Publication number
MX2011007307A
MX2011007307A MX2011007307A MX2011007307A MX2011007307A MX 2011007307 A MX2011007307 A MX 2011007307A MX 2011007307 A MX2011007307 A MX 2011007307A MX 2011007307 A MX2011007307 A MX 2011007307A MX 2011007307 A MX2011007307 A MX 2011007307A
Authority
MX
Mexico
Prior art keywords
gene
cervical cancer
same
vector
stable
Prior art date
Application number
MX2011007307A
Other languages
English (en)
Inventor
Moon-Hee Sung
Haryoung Poo
Il Han Lee
Original Assignee
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Of Bioscience filed Critical Korea Res Inst Of Bioscience
Publication of MX2011007307A publication Critical patent/MX2011007307A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/55—Vectors comprising as targeting moiety peptide derived from defined protein from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un vector de expresión de superficie para la preparación de vacunas contra el VPH, en la cual el vector de expresión de superficie contiene un gen que codifica una proteína mutante repE que tiene una secuencia de aminoácidos de SEQ ID NO: 1, un promotor, un gen complejo poli-gamma-glutamato sintetasa, y un gel el cual está vinculado con el gen complejo de poli-gammato sintetasa y que codifica una proteína antigénica asociada con la inducción de tumor del papilomavirus humano. La presente invención proporciona un vector de expresión constitutivamente que expresa un alto nivel de la proteína antigénica del papilomavirus humano (VPH), También, la invención proporciona una bacteria ácido láctica recombinante, transformada con el vector de expresión y que expresa la proteína antigénica de VPH en la superficie de la misma, y una composición que comprende la bacteria ácido láctica recombinante. La bacteria ácido láctica recombinante y la composición son muy efectivas como una vacuna para el tratamiento del cáncer cervical, porque pueden ser aplicadas por vía oral o directamente a la vagina.
MX2011007307A 2009-01-08 2010-01-08 Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo. MX2011007307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090001510A KR101471043B1 (ko) 2009-01-08 2009-01-08 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균
PCT/KR2010/000126 WO2010079991A2 (ko) 2009-01-08 2010-01-08 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균

Publications (1)

Publication Number Publication Date
MX2011007307A true MX2011007307A (es) 2011-09-21

Family

ID=40791853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007307A MX2011007307A (es) 2009-01-08 2010-01-08 Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo.

Country Status (12)

Country Link
US (1) US8685721B2 (es)
EP (1) EP2386645B1 (es)
JP (1) JP5536803B2 (es)
KR (1) KR101471043B1 (es)
CN (1) CN102341499B (es)
BR (1) BRPI1004898B8 (es)
ES (1) ES2513440T3 (es)
GB (1) GB2466856B (es)
MX (1) MX2011007307A (es)
PL (1) PL2386645T3 (es)
RU (1) RU2492240C2 (es)
WO (1) WO2010079991A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2493846C1 (ru) * 2012-02-03 2013-09-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Минздравсоцразвития России Способ лечения местно-распространенного рака влагалища

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014210747A (ja) 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
DK3254693T3 (da) * 2015-01-30 2021-06-14 Univ Tokyo Mælkesyrebakterieindeholdende sammensætning, oral farmaceutisk sammensætning til at behandle hpv-infektion og/eller hpv-associerede tumorer og slimhindeimmunitietsinducerende middel
KR20200000972A (ko) * 2018-06-26 2020-01-06 주식회사 바이오리더스 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를 이용한 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법
KR102594583B1 (ko) 2018-10-10 2023-10-27 주식회사 비엘 락토바실러스 카제이 유래 갈락토오스 뮤타로테이즈 유전자의 프로모터를 이용한 항시적 고발현 표면발현벡터 및 그 이용
EP3940077A4 (en) * 2018-10-10 2022-08-10 Bioleaders Corporation SURFACE EXPRESSION VECTOR WITH TWO KINDS OF PROMOTERS FROM LACTOBACILLUS CASEI FOR SIMULTANEOUS EXPRESSION OF TWO TARGET PROTEINS AND METHODS FOR EXPRESSING PROTEINS ON A MICROBIAL SURFACE USING THE SAME
US11037655B2 (en) 2019-10-16 2021-06-15 University Of Maryland, Baltimore Microbiome-based informed method to formulate live biotherapeutics
US10967012B2 (en) 2019-10-16 2021-04-06 University Of Maryland, Baltimore Microbiome-based informed method to formulate live biotherapeutics
WO2022103126A1 (ko) * 2020-11-10 2022-05-19 주식회사 바이오리더스 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신
KR20230157180A (ko) * 2022-05-09 2023-11-16 주식회사 비엘 코로나바이러스의 스파이크 단백질, 뉴클레오캡시드 단백질 및 PgsA 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
FI105105B (fi) * 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
KR100366608B1 (ko) 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
ATE342990T1 (de) 2001-08-10 2006-11-15 Bioleaders Corp Oberflächenexpressionsvektoren mit pgsbca, dem für poly-gamma-glutamat-synthetase codierenden gen, sowie verfahren zur expression eines zielproteins an der oberfläche eines den vektor benutzenden mikroorganismus
JP4549858B2 (ja) 2002-10-17 2010-09-22 バイオリーダーズ コーポレイション ヒト・パピローマウイルスに対するワクチン用ベクターおよび同ベクターによって形質転換された微生物
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
KR100872042B1 (ko) * 2005-09-14 2008-12-05 주식회사 바이오리더스 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물
KR100972843B1 (ko) * 2007-03-22 2010-07-28 주식회사 바이오리더스 신규 항시적 고발현 프로모터 및 그 용도
KR101564084B1 (ko) * 2009-01-08 2015-10-29 주식회사 바이오리더스 ｒｅｐＥ 변이유전자를 함유하는 항시적 고발현 벡터

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2493846C1 (ru) * 2012-02-03 2013-09-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Минздравсоцразвития России Способ лечения местно-распространенного рака влагалища

Also Published As

Publication number Publication date
ES2513440T3 (es) 2014-10-27
EP2386645A2 (en) 2011-11-16
GB0907207D0 (en) 2009-06-10
EP2386645A4 (en) 2012-12-26
EP2386645B1 (en) 2014-07-16
RU2011133057A (ru) 2013-03-20
BRPI1004898A2 (pt) 2017-12-12
KR20100082155A (ko) 2010-07-16
BRPI1004898B8 (pt) 2021-05-25
BRPI1004898B1 (pt) 2020-10-13
US20110318384A1 (en) 2011-12-29
JP2012514469A (ja) 2012-06-28
WO2010079991A2 (ko) 2010-07-15
WO2010079991A3 (ko) 2010-11-18
GB2466856A (en) 2010-07-14
JP5536803B2 (ja) 2014-07-02
GB2466856B (en) 2011-06-01
KR101471043B1 (ko) 2014-12-09
US8685721B2 (en) 2014-04-01
CN102341499B (zh) 2014-05-28
PL2386645T3 (pl) 2015-01-30
RU2492240C2 (ru) 2013-09-10
CN102341499A (zh) 2012-02-01

Similar Documents

Publication Publication Date Title
MX2011007307A (es) Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo.
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
WO2010149752A3 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
NZ708144A (en) Recombinant adenoviruses and use thereof
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
NZ628126A (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MY156286A (en) Human il-23 antigen binding proteins
MX2008016036A (es) Vacuna viral recombinante.
MX2009014246A (es) Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.
AU2012342117A8 (en) Recombinant proteins and their therapeutic uses
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
IN2013CN00536A (es)
NZ594198A (en) Neil3 peptides and vaccines including the same
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
WO2012036391A3 (ko) 돼지 써코바이러스２(ｐｃｖ２) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주
WO2008082719A3 (en) Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2012036437A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련 질환 예방 또는 치료용 조성물
NZ606949A (en) Human papillomavirus e7 antigen compositions and uses thereof
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights